iprovalicarb: a derivative of natural amino acid valine & carbamic acid; a fungicide
iprovalicarb : A diastereoisomeric mixture comprising equimolar amounts of L-(R)- and L-(S)-iprovalicarb. It is a systemic fungicide, specific to oomycetes, used on potatoes and grape vines.
isopropyl (3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl)carbamate : A carbamate ester that is valinamide in which one of the hydrogens attached to the amide nitrogen is replaced by a 1-(p-tolyl)ethyl group and the alpha-amino group has been converted to the corresponding isopropyl carbamate.
ID Source | ID |
---|---|
PubMed CID | 6914821 |
CHEBI ID | 83593 |
SCHEMBL ID | 675390 |
MeSH ID | M0471729 |
Synonym |
---|
iprovalicarb |
FT-0670411 |
SCHEMBL675390 |
CHEBI:83593 |
isopropyl (3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl)carbamate |
iprovalicarb-2 |
NWUWYYSKZYIQAE-UHFFFAOYSA-N |
iprovalicarb-1 |
Q27156987 |
propan-2-yl (3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl)carbamate |
DTXSID60861356 |
Iprovalicarb is a carboxylic acid amide (CAA) fungicide. It is highly effective in the control of potato late blight, causing by Phytophthora infestans.
Excerpt | Reference | Relevance |
---|---|---|
"Iprovalicarb is a carboxylic acid amide (CAA) fungicide, highly effective in the control of potato late blight, causing by Phytophthora infestans. " | ( Low evolutionary risk of iprovalicarb resistance in Phytophthora infestans. Chen, F; Li, Y; Qin, C; Zhan, J; Zhou, Q, 2018) | 2.23 |
"Iprovalicarb is a systemic fungicide and has high biological activity with particular efficacy against downy mildew. " | ( Assessment of Iprovalicarb, a systemic fungicide in/on cabbage (Brassica oleracea var. capitata). Maity, A; Mukherjee, I, 2009) | 2.16 |
Excerpt | Reference | Relevance |
---|---|---|
"Iprovalicarb has an excellent toxicological and ecotoxicological profile." | ( Assessment of Iprovalicarb, a systemic fungicide in/on cabbage (Brassica oleracea var. capitata). Maity, A; Mukherjee, I, 2009) | 1.43 |
"Iprovalicarb has been used to control Phytophthora capsici, a devastating pathogen of many economically important crops. " | ( Baseline sensitivity and resistance-risk assessment of Phytophthora capsici to iprovalicarb. Bi, Y; Hao, JJ; Liu, XL; Lu, XH; Zhu, SS, 2010) | 2.03 |
Excerpt | Reference | Relevance |
---|---|---|
" This study will be useful for promoting effective residue management and the safe use of these chemicals for controlling fungal diseases in grapes." | ( Dissipation kinetics, safety evaluation, and decontamination of residues of the combo-formulation iprovalicarb 8.4% + copper oxychloride 40.6% WG in/on grapes ( Hingmire, S; Kadam, P; Shabeer Tp, A; Taynath, B; Verma, Y, 2022) | 0.94 |
Class | Description |
---|---|
carbamate ester | Any ester of carbamic acid or its N-substituted derivatives. |
valine derivative | An amino acid derivative resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of valine by a heteroatom. The definition normally excludes peptides containing valine residues. |
amino acid amide | An amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.75) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |